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African  horse  sickness  (AHS)  is  an  equine  disease  with  a mortality  of  up  to  90%  for  susceptible  horses.
The  causative  agent  AHS  virus  (AHSV)  is  transmitted  by species  of  Culicoides.  AHSV  serogroup  within  the
genus  Orbivirus  of  the  Reoviridae  family  consists  of  nine  serotypes  that  show  no or very  limited  cross-
neutralization.  Of the  seven  structural  proteins  (VP1-VP7)  of AHSV,  VP2  is  the serotype  speciﬁc  protein,
and  the  major  target  for  neutralizing  antibodies.  In this  report,  recombinant  VP2  proteins  of  all  nine
serotypes  were  expressed  individually  by the  baculovirus  expression  system  and  the immunogenicity  of
each  was studied  by  immunization  of  guinea  pigs  with  single  VP2  as  well  as  with  cocktails  of VP2  proteins.
Homologous  neutralizing  antibodies  measured  by  50%  plaque  reduction  assay  showed  varying  degreesapsid protein VP2
ubunit vaccine
(from  37 to  1365)  of titers  for different  VP2  proteins.  A  low  cross-neutralizing  antibody  titer  was  found
for  genetically  related  AHSV  serotypes.  Immunization  with  VP2  cocktails  containing  equal  amounts  of
each  of the VP2  proteins  also  triggered  neutralizing  antibodies  albeit  to  lower  titers  (4-117) to  each  of
the  serotypes  in  the cocktail.  This study  is  a ﬁrst step  to develop  a VP2  subunit  vaccine  for  AHS  and  our
results  indicate  that  VP2  subunit  vaccines  are  feasible  individually  or in a multi-serotype  cocktail.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
African horse sickness virus (AHSV) is the causative agent of
frican horse sickness (AHS) which is lethal for up to 90% of infected
omestic horses [1]. AHSV infections of zebras and donkeys are
ess severe and mostly cause mild clinical symptoms or an asymp-
omatic infection. These equids are carriers of AHSV, which is
ransmitted by Culicoides midges, in particular by C. imicola in
ndemic areas [1,2]. It is believed that the distribution of AHSV is
ssociated with the presence of these competent vectors. Currently,
HSV is endemic in tropical and sub-Saharan Africa, but sporadic
ases and short-term epidemics in North Africa and Middle-East
ave been reported in the mid-20th century. In 1987, an outbreak
f AHSV-4 on the Iberian Peninsula, which was extended for a few
ears in Spain and spread to Portugal and Morocco indicating that
HSV had overwintered and spread by European Culicoides midges
1,3].
∗ Corresponding author. Tel.: +44 0207 927 2324; fax: +44 0207 637 4314.
E-mail addresses: polly.roy@lshtm.ac.uk, pollyroy.ofﬁce@lshtm.co.uk (P. Roy).
ttp://dx.doi.org/10.1016/j.vaccine.2014.07.031
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
The serogroup AHSV within the genus Orbivirus of the Reoviri-
dae family consists of nine serotypes (AHSV-1 – AHSV-9). The
virus particle contains ten genome segments of double-stranded
RNA (dsRNA) encoding seven structural proteins (VP1-VP7). Addi-
tionally, at least three non-structural proteins (NS1-NS3) are
synthesized in virus infected cells. The virus particle consists of
three distinct protein layers, of which the VP2 and VP5 proteins
form the outer shell and are the most variable proteins of AHSV.
Dominant antigenic sites inducing serotype speciﬁc neutralizing
antibodies (nAbs) are mainly located on VP2, however, other struc-
tural and non-structural proteins – VP3, VP5, VP7, NS1 and NS2 –
also induce humoral and cellular immune responses [4–9].
Since there is no successful treatment for AHS, vaccination is
the most important approach to protect horses against AHS. Live-
attenuated vaccines (LAVs) obtained by serial passages of AHSV in
cell culture are available commercially for most serotypes in South
Africa [1]. Although LAVs have been extensively used in South Africa
and other African countries, there are still concerns as LAVs cause
viremia and could be transmitted by midges. However, the biggest
concern of using these vaccines is reassortment between LAVs or
with wild type AHSV, which could result in more pathogenic virus
variants. Moreover, the recent outbreak of AHSV serotype 9 in
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ambia is suspected to be derived from vaccine strains [10].
urrently, LAVs are not licensed in Europe. To overcome safety
ssues, alternative AHS vaccines are under development including
nactivated virus, recombinant VP2, DNA vaccine and vaccinia virus
ectors expressing VP2 protein [11–19].
Outer capsid protein VP2 of orbiviruses determines the serotype
nd is the main target of nAbs [20–23]. Vaccination with recom-
inant VP2 of AHSV serotype 4, 5 or 9 has been reported to
nduce nAbs and protect horses against homologous AHSV chal-
enge infection [13,14,16,18,19,22,24]. To date, there are no reports
egarding the immunogenicity of VP2 proteins of other serotypes
f AHSV. In this report, VP2 of all nine AHSV serotypes were pro-
uced individually using the baculovirus expression system and
heir immunogenic activities were investigated by immunization
f guinea pigs, singly or in cocktail mixtures. The results demon-
trated that recombinant VP2 proteins of all nine AHSV serotypes
ave the potential to be used as safe subunit vaccines for AHS either
ndividually or in a multi-serotype cocktail.
. Materials and methods
.1. Viruses and cells
AHSV reference strains (obtained from ANSES, France) were pas-
aged and ampliﬁed in BSR cells, a derivative of the BHK-21 cell line,
n Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Sigma) supple-
ented with 10% fetal bovine serum (Invitrogen). Virus titers were
etermined by a plaque-forming assay in BSR cells and deﬁned as
laque forming units per ml  (pfu/ml) as described [25]. Insect cell
ines of Spodoptera frugiperda, Sf9 and Sf21, were cultured at 28 ◦C
n Insect-Xpress (Lonza, Basel, Switzerland) and TC100 medium
Biochrom AG, Berlin, Germany), respectively. TC100 medium was
upplemented with 10% fetal bovine serum.
.2. Preparation of recombinant AHSV VP2 protein
Genome segment 2 of AHSV serotypes 2, 4, 5 and 6, encoding
P2 were obtained from viral dsRNA according to the previously
escribed method [26]. For AHSV serotypes 1, 3, 7, 8 and 9,
pen reading frames based on amino acid sequences of VP2 pro-
eins (GenBank accession number: CAP04841; U01832; AAN74570;
BI96883, respectively), were designed for optimized expression
n insect cells (Gene Art, Regensburg, Germany). VP2 genes were
mpliﬁed by PCR with speciﬁc primers containing BamHI or SmaI
ite for cloning purposes into the transfer vector pAcYM1 [27].
Recombinant vectors pAcYM1 with VP2 genes were puriﬁed and
o-transfected into Sf9 cells with linearized baculovirus DNA (strain
AC10:KO1629), using Cellfectin® II Reagent (Invitrogen) accord-
ng to the manufacturer’s instruction. On day six after transfection,
00 l of the supernatants were transferred to fresh Sf9 cells in
2-wells plates. After the ﬁrst passage, supernatants were trans-
erred to fresh Sf9 cells every 3–5 days until virus infection was
onﬁrmed by light microscopy. The virus titer was measured by
tandard plaque assay using Sf21 cells.
.3. Preparation of soluble VP2 protein
Recombinant baculoviruses expressing AHSV VP2 were used to
nfect Sf9 cells with a multiplicity of infection (moi) of 5. Infected
ells were incubated at 28 ◦C for 72 h. Then, infected cells were har-
ested by centrifugation, washed with phosphate buffered saline
PBS) and pelleted by centrifugation. Cell pellets were suspended
n 25 mM sodium bicarbonate (NaHCO3, pH 8.39) at 1.0 × 107
ells/ml. Cells were disrupted by dounce homogenization and after
entrifugation at 6000 rpm for 3 min, supernatants containing sol-
ble VP2 protein were collected. To examine the amount of VP2 (2014) 4932–4937 4933
proteins, soluble VP2 were mixed with equal volumes of SDS-
PAGE sample buffer (10 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 2%
-mercaptoethanol, 20% glycerol, 0.05% bromophenol blue). After
heating at 95 ◦C for 1 min, the samples were analyzed by SDS-PAGE
with BSA as concentration standard and protein molecular weight
standard (Page Ruler, SM0671, Fermentas). Concentrations of all
samples were adjusted to 100 g of VP2 per ml  by 25 mM sodium
bicarbonate and stored at −80 ◦ C until use.
2.4. Immunization of soluble VP2 in guinea pigs
All experiments with live animals were performed under
the guidelines of the European Community (86/609) and were
approved by the Committee on the Ethics of Animal Experiments
of the Central Veterinary Institute (Permit numbers: 2011-042 and
2011-170). Adult female guinea pigs were purchased from a regis-
tered breeding farm for guinea pigs and were randomly divided into
groups of six animals. Nine groups were immunized with VP2 pro-
tein from each AHSV serotype, two groups were immunized with
cocktails of different combinations of VP2 proteins (one consisting
of serotypes 1, 3, 7, 8 and other, serotypes of 2, 4, 5, 6, 9, respec-
tively) and one group was  immunized with phosphate buffered
saline (PBS). Shortly before immunization, recombinant VP2 pro-
teins or PBS in 1.5 ml  were warmed to 37 ◦C and mixed with an
equal volume of Montanide 206VG (Seppic) by vortexing. Each ani-
mal  received 400 l containing adjuvanted 50 g of VP2 protein
by subcutaneous injection of 100 l at four places left and right
from the spinal cord. Cocktails contained equal amounts of each
VP2; 12.5 g of each VP2 (1, 3, 7 and 8) or 10 g of each VP2 (2,
4, 5, 6 and 9). At day 21, all guinea pigs were boosted by the same
procedure and with the same amount of proteins. At day 42 of the
experiment, animals were sacriﬁced and sera were collected.
2.5. Detection of neutralizing antibodies (nAbs)
Guinea pig sera collected at the end of the experiment, day 42,
were examined for nAbs by plaque reduction based standard neu-
tralizing assay [21]. Brieﬂy, serially 2-fold diluted sera in DMEM
were mixed with an equal volume of each AHSV reference strain
virus (20–40 pfu/25 l) and incubated at 37 ◦C for 60 min  in a 5%
CO2 incubator. As a control, each virus was  mixed with an equal
volume of DMEM without any serum. After incubation, 50 l neu-
tralized viruses were used to infect BSR monolayers in a 12-well
plate. After absorption of virus for 1 h at 37 ◦C, cells were overlaid
with DMEM-  1% low-melting agarose gel, followed by incubation
at 37 ◦C for 2–4 days until plaques were visible. The neutraliza-
tion titers were calculated by the reciprocal value of the maximum
dilution, at which the number of plaques showed 50% reduction
compared with the serum-free control. The neutralizing tests were
performed in duplicate. The average and 95% conﬁdence interval
was calculated in each group.
2.6. Immunostaining of AHSV-infected monolayers
Equal volumes of sera from guinea pigs of each group col-
lected at the end of the experiment were pooled and examined
for AHSV speciﬁc antibodies (Abs) by immunoperoxydase mono-
layer assay (IPMA). Pooled sera collected prior to immunization
(day 0) were used as negative control serum. In brief, BSR mono-
layers were infected at low multiplicity of infection with each of
the reference strains representing all nine AHSV serotypes, respec-
tively. At the beginning of cytopathic effect (CPE), medium was
removed and monolayers were washed with PBS, and ﬁxed with
methanol/acetone (1:1) according to standard procedures. Mono-
layers were stained by IPMA with sera diluted 1:500, followed by
4934 Y. Kanai et al. / Vaccine 32 (2014) 4932–4937
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sig. 1. Expression of recombinant VP2 proteins of nine AHSV serotypes in Sf9 cells:
roteins (121–124 kDa) are indicated by arrow heads.
ncubation with conjugated -guinea pig rabbit serum (DAKO) and
tained according to standard procedures [28].
.7. Phylogenetic tree
Phylogenetic trees of the AHSV VP2 deduced amino acid
equences were constructed using 39 sequences of AHSV VP2
btained from GenBank by the neighbor-joining method using
EGA 4.1 software.
. Results
.1. Expression of recombinant AHSV VP2 of 9 serotypes
Recombinant VP2 proteins of nine AHSV serotypes were
xpressed in Sf9 cells using the baculovirus expression system with
P2 genes under the control of the polyhedron promoter. Higher
xpression of VP2 was obtained with codon optimized VP2 genes
or serotypes 1, 3, 7, 8 and 9 than with the original VP2 sequences
or serotype 2, 4, 5 and 6 (Fig. 1). The differences in VP2 expres-
ion were less obvious in Sf21 cells as shown in our previous study
29]. Soluble VP2 protein of each serotype was harvested at 72 h
ost-infection. Recombinant baculovirus-infected cells were col-
ected by centrifugation and lysed by homogenization in 25 mM
odium bicarbonate. After centrifugation, the clariﬁed supernatant
as used for immunization of guinea pigs. Concentrations of VP2
rotein were estimated at 100 g/ml by comparing with bovine
erum albumin (BSA) standard on a Coomassie Brilliant Blue stained
DS-PAGE gel.
.2. Immunogenicity of AHSV VP2 proteins in guinea pigs
Guinea pigs were immunized twice with 50 g of VP2 protein
fter mixing with an equal volume of Montanide 206VG accord-
ng to a prime-boost protocol with an interval of 3 weeks. At
ay 42 of the experiment, sera were collected and tested for the
eutralization activities as described in Section 2. Immunization
ith a single VP2 protein induced serotype speciﬁc nAbs (Table 1).
espite the same amount of recombinant VP2 proteins being used
n each group and in each guinea pig, serotype speciﬁc nAb titers
trongly varied between groups, and also between animals withinins were separated on a SDS-PAGE gel and stained by Coomassie Brilliant Blue. VP2
the same group. For example, nAb titers ranged from 37 (95% con-
ﬁdence interval (CI): 27–48) for AHSV-2 to as high as 1365 (95% CI:
942–1788) for AHSV-6.
Two groups of animals injected with the cocktails containing
VP2 proteins of serotypes 1, 3, 7 and 8, and of 2, 4, 5, 6 and 9, respec-
tively, had nAb titers to the included AHSV serotypes (Table 1).
However, nAb titers against each of the AHSV serotypes were con-
sistently lower than those after immunization with single VP2
proteins. It is possible that this is due to the 4–5 times lower dose
per VP2 protein in the cocktails compared to the single VP2 immu-
nization; i.e. 50 g of VP2 proteins were inoculated for single VP2
vaccination, whereas 10 g per VP2 in the pentavalent cocktail and
12.5 g per VP2 in the quadrivalent cocktail was  injected. The lower
nAb titer by cocktails compared to single VP2 protein varied from
3 to 4 times lower for serotype 5 to ∼45 times lower for serotype 9
after immunization with these VP2 proteins in cocktails (Table 1).
Importantly, some cross-neutralization was also detected for a few
genetically related serotypes (Fig. 1) [30]. For example, -AHSV-
3 VP2 serum for serotype 7, -AHSV-5 VP2 serum for serotype
8, and -AHSV-6 and -AHSV-9 VP2 serum both showed nAbs
titers for the genetically related serotype: i.e. serotype 9, and 6,
respectively (Table 1). However, these cross-reactive nAb titers are
>40 times lower than the nAb titer against the respective homolo-
gous serotypes used for immunization. Further, no signiﬁcant nAb
titers against genetically unrelated serotypes were found. Immu-
nization with VP2 cocktails did not result in signiﬁcant nAbs titers
against genetically unrelated serotypes, and only a very low nAb
titer against a related serotype (-AHSV-5 VP2 serum for serotype
8) could be detected (Table 1).
3.3. Serotype speciﬁcity of guinea pig sera raised against
recombinant VP2 proteins
Titers of nAbs raised against different VP2 proteins demon-
strated a high level of serotype speciﬁcity. Non-neutralizing Abs
still could cross-react between serotypes by binding to com-
mon  epitopes. Therefore, serotype speciﬁcity was  further studied
by immunoperoxydase monolayer assay (IPMA). Pooled sera per
group were 500-fold diluted and used in IPMA to immunostain
BSR monolayers infected with each of the nine reference AHSV
strains. As expected, guinea pig sera raised against single VP2
Y. Kanai et al. / Vaccine 32 (2014) 4932–4937 4935
Table  1
Titers of neutralizing antibodies (nAbs) raised in guinea pigs.
Guinea pig groups (n = 6)
1 2 3 4 5 6 7 8 9 1, 3, 7, 8 2, 4, 5, 6, 9 Control
AHSV 1 112 11
(48–176) (2–19)
AHSV 2 37 10
(27–48) (1–19)
AHSV 3 341 19
(236–447) (11–28)
AHSV 4 171 12
(118–224) (9–16)
AHSV 5 179 53
(14–345) (40–67)
AHSV 6 1365 12 117
(942–1788) (3–21) (58–177)
AHSV 7 8 122 20
(3–13) (46–197) (12–28)
AHSV 8 3 96 4 2
(1  –4) (10–87) (2–7) (0–4)
AHSV 9 24 853 19
(17–31) (642–1065) (10–27)
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Abs  against each of the AHSV serotypes (AHSV-1–AHSV-9) were determined. The 
rackets. Titers of nAbs <2 were evaluated as 0.
roteins immunostained monolayers infected with the homolo-
ous AHSV serotype (Table 2). Similar to cross-neutralization of
enetically related AHSV serotypes, some monolayers infected with
enetically related AHSV serotypes were also immunostained. In
ontrast to the cross-neutralization results (Table 1), AHSV-6 was
ot recognized by -AHSV-9 VP2 serum (Table 2). In addition to
mmunostaining of genetically related AHSV serotypes, some unre-
ated AHSV reference strains were also recognized in IPMA; e.g.
HSV-8 was recognized not only by -VP2 sera of AHSV-5 and -8
ut also by AHSV-4. AHSV-5 was also recognized by -VP2 of
HSV-3. In general this immunostaining was weaker than for the
espective homologous AHSV serotype (Table 2).
. Discussion
VP2 protein of orbiviruses is the major determinant of eliciting
Abs and has been used as recombinant protein-based vaccine in
revious studies [17,21–23,31]. Particularly, VP2 of AHSV serotype has been studied extensively by European research groups, as
he last European AHS outbreak was caused by this serotype [32].
n this report we studied the immunogenicity of VP2 proteins of
ll nine AHSV serotypes as a ﬁrst step in the development of AHS
able 2
PMA results with pooled sera raised in guinea pigs.
Guinea pig groups (n = 6)
1 2 3 4 5 6 
AHSV 1 +++ 
AHSV  2 +++ 
AHSV  3 +++ 
AHSV  4 +++ 
AHSV  5 ++ +++ 
AHSV  6 +++ 
AHSV  7 ++ 
AHSV  8 ++ +++ 
AHSV  9 ++ 
ingle VP2 proteins (1–9) or with cocktails of 4 or 5 different VP2 proteins (1, 3, 7, 8 or
onolayers were infected with each of the AHSV serotypes (AHSV1–AHSV9), and immu
-guinea pigs rabbit serum. Staining was semi-quantitated by +++, ++, + for strong, mediu 4, 5, 6, 9, respectively) were used to immunize six guinea pigs per group. Titers of
e nAb titers were calculated and the 95% conﬁdence interval is indicated between
subunit vaccines. This is the ﬁrst report to show that VP2 of all nine
AHSV serotypes induce serotype speciﬁc nAbs with slight cross-
neutralizing antibodies. The baculovirus expression system was
used to produce recombinant VP2 protein of all nine serotypes
for induction of nAbs. Further, some VP2 genes were optimized to
increase protein expression. Still, quantities of soluble VP2 signiﬁ-
cantly varied between the different serotypes. Since it is generally
known that recombinant VP2 protein of orbivirus is highly insol-
uble, it is likely that quantities of soluble VP2 proteins vary by
differences in expression or solubility [33].
VP2 proteins of each AHSV serotype were produced in insect
cells and each induced detectable nAb titers in guinea pigs as an
alternative animal model. Previously, puriﬁed AHSV VP2 seemed to
be less immunogenic in rabbits [21], but as little as 5 g of VP2 pro-
tein in insect cell lysate could protect horses from AHS by induction
of nAbs [14]. In this study, guinea pigs were immunized with insect
cell lysate containing 50 g of VP2 to elicit detectable antibodies.
Each VP2 elicited serotype speciﬁc Abs, but nAb titers varied con-
siderably among different AHSV serotypes, from 37 for AHSV-2 to
1365 for AHSV-6. Further, cross-neutralization antibodies between
genetically related serotypes were detected, but most of those
cross-neutralizing Abs titers were considerably lower than for the
7 8 9 1, 3, 7, 8 2, 4, 5, 6, 9 Control
+++
+++
+++
+++ ++
+++ ++ +++
+++
+++ +++
++ ++ ++
+++ +
 2, 4, 5, 6, 9, respectively) were used to immunize six guinea pigs per group. BSR
nostained by binding of guinea pig antibodies followed by binding of conjugated
m, and weak staining, respectively.
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Fig. 2. Phylogenetic analysis of AHSV VP2 protein: VP2 sequences from a total of 39936 Y. Kanai et al. / Vacc
espective serotype. Moreover, some expected cross-reactive nAbs
ere not detected. This lack of expected cross-reactive nAbs are
ost likely due to low titer of cross-reactive nAbs compared with
erotype speciﬁc nAbs. Unfortunately challenge experiments could
ot be performed in guinea pigs, as horses are the natural host for
HSV. The AHSV infection model using interferon- knockout mice
ere recently reported [17]. The use of the small animal model for
ur future VP2 vaccine study should help to evaluate the vaccine
fﬁcacy.
Cross-reactive Abs to genetically related AHSV serotypes were
hown by IPMA with lower Ab titers than serotype speciﬁc reac-
ions, except for AHSV-5 and AHSV-8, in which -AHSV-5 VP2
erum reacted strongly to both AHSV-5 and AHSV-8, and vice versa.
nterestingly, no cross neutralization Abs between AHSV-5 and
HSV-8 were detected. It would be thought that more antibod-
es to non-neutralizing than to neutralizing domains of AHSV-5
nd AHSV-8 VP2 were elicited. These variations in the feasibil-
ty of eliciting non-neutralizing Abs and nAbs between serotypes
ould contribute the considerable differences in the nAb titers.
lthough the crystal structure of AHSV VP2 has not been solved,
eutralizing domains on the secondary structure containing amino
cid 199–689 of VP2 were demonstrated [34]. To avoid eliciting
on-neutralizing Abs, expression and immunization of only neu-
ralization domain of VP2 may  help to induce nAbs more efﬁciently.
n contrast to AHSV-5 and -8, VP2 of AHSV serotype 9 induced nAbs
gainst serotype 6 (nAb titer of 12 with 95% CI: 3–21) which was not
etectable by IPMA, suggesting that the non-nAb is not necessarily
igher than nAb. This phenomenon is probably due to the structural
imilarity and dissimilarity between VP2s of relevant serotypes.
Here, we have also studied two cocktails of four or ﬁve VP2 pro-
eins. The results suggested a dose-dependent immune response,
ince all serotype speciﬁc nAb titers were lower after immunization
ith cocktails of VP2 proteins (10/12.5 g of each VP2 per animal)
han those with individual VP2 immunization (50 g of VP2 per
nimal). However, this reduction was not linearly related to the
mount of injected VP2. The reduction of 4–5 fold VP2 protein in
ocktails resulted in 4 to 40 fold reduced nAb titers compared to
ingle VP2 immunization; e.g. for serotype 5, 179 by single and 53
y cocktail VP2 (±30% difference), and for serotype 9, 853 by single
nd 19 by cocktail VP2 (±2% difference). This might suggest a neg-
tive interference between some of the VP2 proteins in cocktails
o induce nAbs. The lower serotype speciﬁc nAb titer after immu-
ization with cocktails of VP2 proteins could also be due to the
imultaneous presentation of various serotype speciﬁc epitopes to
he immune system or due to the immunodominance of certain
erotype speciﬁc epitopes. Thus, formulation of VP2 cocktails to
rotect horses against all included serotypes is also complicated by
ifferences in immunogenicity and possible interference between
P2 proteins to induce humoral immune responses.
We  intended to induce humoral responses against closely
elated and possibly more serotypes than included in the cocktail
y a prime-boost approach [35]. However, genetically related VP2
roteins 3 and 7, or 5 and 8, (Fig. 2) in each of the cocktails did not
ncrease nAbs titers against their related serotypes. No nAbs were
etected against unrelated serotypes (Table 1). Further, nAb titers
gainst each VP2 protein differed strongly after immunization with
 cocktail or with single VP2 protein. Non-neutralizing Abs were
aised by cocktails of VP2 proteins; i.e. Abs against serotype 4, 5
nd 9 by the cocktail of 1, 3, 7, 8, and Abs against serotype 8 by
he cocktail of 2, 4, 5, 6, 9 (Table 2). Perhaps, AHSV serotypes have
ommon epitopes on VP2 but these differ in avidity or afﬁnity for
hese Abs. As a result, binding to epitopes occurs and will immunos-
ain AHSV infected monolayers but this binding will not neutralize
HSV.
Currently used cocktails of live-attenuated vaccines (LAVs)
nduce a broader protection. Even LAV for serotype 5 and 9 areisolates of 9 serotypes (obtained from GenBank) were used to deduce amino acid
residues in order to generate the phylogenetic tree by the neighbor-joining method
using MEGA 4.1 software.
not included, and protection against AHSV-5 and -9 are achieved by
serotype-related LAVs for serotype 8 and 6, respectively [36]. How-
ever, when using cocktails of LAVs it was also suggested that there
are substantial differences in cross-reactivity between serotypes;
e.g. cross-reactivity between AHSV-5 and -8 seems to be stronger
than between AHSV-6 and -9 [37]. Importantly, undesirable events
such as reversion to virulence and reassortment between LAVs
or with ﬁeld virus are highly likely. Furthermore, LAVs induce an
immune response against all viral proteins and are therefore not
‘DIVA’ (differentiating infected from vaccinated animals) vaccines.
In contrast, VP2 subunit vaccine induces Abs solely against VP2, and
horses vaccinated with VP2 subunit vaccines should therefore be
seronegative for VP7 antibodies. An AHSV infection results rapidly
in seroconversion for VP7 antibody and VP7 is the target for several
commercially available tests to detect AHSV infections. DIVA test-
ing by these commercially available tests will be very supportive
in combination with vaccination with VP2 subunit vaccine. Thus,
rapid control of AHS outbreaks as well as conﬁrming the virus-free
status of animals for international movements irrespective of the
vaccination status can be achieved with the current available and
extensively validated VP7 ELISA.
In summary, we  demonstrated that multi-serotype VP2 subunit
vaccines for AHS are potentially feasible, as shown here by immu-
nization of guinea pigs as an alternative animal model. The guinea
pig model can be initially used for immunogenicity studies in order
to reduce experiments in horses. The considerable difference in
immunogenicity between VP2 proteins in guinea pigs has to be
taken into account and should be investigated further prior to the
formulation of single as well as cocktail VP2 subunit vaccines for
African horse sickness.
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